$BCDA News

BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US

What's Going On With BioCardia Stock Tuesday?

HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target

BioCardia Sells 3,509,604 Shares At Average Price Of $1.279 On June 5; No Warrants Issued In Capital Raise

Why Is BioCardia Stock Gaining Friday?

BioCardia Receives FDA Confirmation For Its Biologics Evaluation And Research On CardiAMP Cell Therapy System To Treat Ischemic Heart Failure Of Reduced Ejection Fraction

BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes

BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript

BioCardia Q1 2026 Earnings Call: Complete Transcript

BioCardia Inc (NASDAQ:BCDA) Q1 Earnings Miss Overshadows Clinical Progress

BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate

BioCardia Says FDA Raised No Safety Concerns, Outlines Two Clearance Pathways For Helix Catheter System

BioCardia Announces Allowance Of Japanese Patent Titled "Target Site Selection, Entry, and Update with Automatic Remote Image Annotation."

BioCardia Announces Allowance Of Japanese Patent Titled "Target Site Selection, Entry, and Update with Automatic Remote Image Annotation."

Japan's Pharmaceutical and Medical Device Agency Finds BioCardua's CardiAMP Cell Therapy Sufficient To Support Market Clearance

BioCardia Files Request For FDA Meeting Related To Approval For CardiAMP System For Ischemic Chronic Heart Failure

BioCardia, Inc. Q4 2025 Earnings Call Summary

BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ...

BioCardia, Inc. 2025 Q4 - Results - Earnings Call Presentation

BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript